

+

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete If Known

(use as many sheets as necessary)

1

Q

2

New Application	10	685,124
-----------------	----	---------

Dvorak, et al.

unassigned	1624
------------	------

unassigned

R0067C-REG

U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
DR	A1	5,693,630		Bengtsson et al	Dec. 2, 1997	
	A2	5,382,595		Minami et al	Jan. 17, 1995	
	A3	5,177,089		Minami et al	Jan. 5, 1993	
	A4	5,047,417		Minami et al	Sept. 10, 1991	
	A5	5,607,953		Minami et al	Mar. 4, 1997	
	A6	3,354,178		Dickinson	Nov. 21, 1967	
	A7	4,065,471		Dickinson	Dec. 27, 1977	
	A8	4,087,541		Eberlein et al	May 2, 1978	
	A9	4,038,407		Eberlein et al	July 26, 1977	
	A10	4,490,369		Reiffen et al	Dec. 25, 1984	
	A11	3,054,794		Shapiro et al	Sept. 18, 1962	
	A12	5,998,452		Ohi et al	Dec. 7, 1999	
✓	A13	4,729,994		Carson	Mar. 8, 1988	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₀
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
WJR	B1	FR	2,302,733		Karl Thomae GmbH	Oct. 1, 1976		
↓	B2	EP	0259,793	B1	Karl Thomae GmbH	March 16, 1988		
↓	B3	WO	99/43657		Hoffmann-La Roche AG	Sept. 2, 1999		

W. Mark Berry

10/3/05

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231 **doc. #113572**

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet **2** of **2**

Complete if Known

Application Number	New Application 10/685,124
Filing Date	
First Named Inventor	Dvorak, et al.
Group Art Unit	unassigned 1624
Examiner Name	unassigned
Attorney Docket Number	R0067C-REG

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
BR	C1	SINGH, et al., "Studies in Potential Filaricides: Part VIII – Synthesis of 1-Ethyl-3-(2-dialkylaminoethyl)-& 1,3-Diethyl-4-dialkylaminoethyl-hexahydropyrimidin-2-ones," <u>Indian Journal of Chemistry</u> , (1976), pp. 528-531, vol. 14	
	C2	GLOZMAN, et al, "Synthesis and cardiovascular properties of 1-dialkyl-aminoalkyl-4-arylpyrrolidones-2", <u>Khim.-Farm.Zh.</u> , (1996), pp. 11-14, 30(4), Russia	
	C3	EHLERT, et al., "Subtypes of the Muscarinic Receptor in Smooth Muscle", (Minireview), <u>Life Sciences</u> , (1997), pp. 1729-1740, vol. 61	
	C4	HEDGE, et al., "Muscarinic Receptor Subtypes Modulating Smooth Muscle Contractility in the Urinary Bladder", <u>Life Sciences</u> , (1999), pp. 419-428, vol.64	
	C5	EGLIN, et al., "Muscarinic acetylcholine receptor subtypes in smooth muscle", <u>Trends. Pharmacol. Sci.</u> , (1994), pp. 114-119, vol. 15	
	C6	EGLIN, et al, "Muscarinic receptor subtypes and smooth muscle function", <u>Pharmacol. Rev.</u> , (1996), pp. 531-565, V. 48, No.4	
	C7	NILVEBRANT, et al., "Tolterodine – A new Bladder Selective Muscarinic Receptor Antagonist: Preclinical Pharmacological and Clinical Data", <u>Life Sciences</u> , (1997), pp. 1129-1136, vol. 60	
	C8	ALABASTER, "Discovery & Development of Selective M ₃ Antagonists for Clinical Use", <u>Life Sciences</u> , (1997), pp. 1053-1060, Vol. 60, Nos. 13/14:	
	C9	OSAYU, et al, "Urinary Bladder-selective Action of the New Antimuscarinic Compound Vamicamide", <u>Drug Res.</u> , (1994), pp. 1242-1249, Vol. 44(II) No. 11	
	C10	HOMMA, et al, –Abstract, "Randomized Double-Blind Study to Compare Clinical Efficacy of Temiverine and Propiverine for Unstable Bladder and Detrusor Hyperreflexia", <u>Neurology and Urodynamics</u> , (1997), pp. 345-346, Vol. 16	
	C11	EGLIN and Hegde, – Chapter 4, "Selective modulation of muscarinic receptor subtypes: therapeutic potential", <u>Emerging Drugs</u> , (1998), pp. 67-79, Vol. 3, Ashley Publications Ltd.	
	C12	EGLIN, et al, "Muscarinic receptor ligands and their therapeutic potential", <u>Curr. Opin. Chem. Biol.</u> , (1999), pp. 426-432, Vol. 3	
✓	C13	CAULFIELD, et al, "International Union of Pharmacology. XVII. Classification of Muscarinic Acetylcholine Receptors", <u>Pharmacological Reviews</u> , (1998), pp. 279-290, Vol. 50(2):	

Examiner
Signature

Dmytro Reyz

Date
Considered

10/3/05